First Results of Avicidin Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation studies, Avicidin produced a 10-fold improvement in tumor-to-blood ratios over conventional radioimmunotherapy, approaching the ratios achieved in animal studies.

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalationstudies, Avicidin produced a 10-fold improvement in tumor-to-bloodratios over conventional radioimmunotherapy, approaching the ratiosachieved in animal studies.

Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx'sproprietary pretargeting technology in which the radionuclideand antibody are injected separately rather than linked together.The radionuclide either attaches to the antibody that is pretargetedto the tumor or quickly exits the body, reducing radiation exposureto normal tissues, NeoRx said.

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer